Prevalence of Candida glabrata and its response to boric acid vaginal suppositories in comparison with oral fluconazole in patients with diabetes and vulvovaginal candidiasis

Diabetes Care

Volumn 30, Issue 2, 2007, Pages 312-317

  Ray, Debarti ^a   Goswami, Ravinder ^a   Banerjee, Uma ^a   Dadhwal, Vatsla ^a   Goswami, Deepti ^b   Mandal, Piyali ^a   Sreenivas, Vishnubhatla ^a   Kochupillai, Narayana ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b MAULANA AZAD MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BORIC ACID; FLUCONAZOLE; HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT;

ADULT; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FUNGUS ISOLATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SUPPOSITORY; TREATMENT OUTCOME; VAGINA CANDIDIASIS; VAGINAL BURNING SENSATION;

ADMINISTRATION, ORAL; ADULT; ANTIFUNGAL AGENTS; BORIC ACIDS; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDIASIS, VULVOVAGINAL; FEMALE; FLUCONAZOLE; HUMANS; MIDDLE AGED; SUPPOSITORIES; VAGINA;

EID: 33846677718     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc06-1469     Document Type: Article

References (35)

1. Sonck CE, Somersalo O: The yeast flora of anogenital region in diabetic girls. Arch Dermatol 83:214-220, 1963
2. Reed BD: Risk factors for Candida vulvo vaginitis. Obstet Gynecol Surv 47:551-560, 1992
3. Peer AK, Hoosen AA, Seedat MA, van den Ende J, Omar MA: Vaginal yeast infections in diabetic women. S Afr Med J 83:727-729, 1993
4. Goswami R, Dadhwal V, Tejaswi S, Datta K, Paul A, Haricharan RN, Banerjee U, Kochupillai NP: Species-specific prevalence of vaginal candidiasis among patients with diabetes mellitus and its relation to their glycaemic status. J Infect 41:162-166, 2000
5. Bohannon NJ: Treatment of vulvovaginal candidiasis in patients with diabetes. Diabetes Care 21:451-456, 1998
6. de Leon EM, Jacober SJ, Sobel JD, Foxman B: Prevalence and risk factors for vaginal Candida colonization in women with type 1 and type 2 diabetes. BMC Infect Dis 2:1, 2002
7. Jurevic RJ, Bai M, Chadwick RB, White TC, Dale BA: Single-nucleotide polymorphisms (SNPs) in human beta-defensin 1: high-throughput SNP assays and association with Candida carriage in type I diabetics and nondiabetic controls. J Clin Microbiol 41:90-96, 2003
8. Goswami D, Goswami R, Banerjee U, Dadhwal V, Miglani S, Lattif AA, Kochupillai N: Pattern of Candida species isolated from patients with diabetes mellitus and vulvovaginal candidiasis and their response to single dose oral fluconazole therapy. J Infect 52:111-117, 2006
9. Corsello S, Spinillo A, Osnengo G, Penna C, Guaschino S, Beltrame A, Blasi N, Festa A: An epidemiological survey of vulvovaginal candidiasis in Italy. Eur J Obstet Gynecol Reprod Biol 110:66-72, 2003
10. Redondo-Lopez V, Lynch M, Schmitt C, Cook R, Sobel JD: Torulopsis glabrata vaginitis: clinical aspects and susceptibility to antifungal agents. Obstet Gynecol 76:651-655, 1990
11. vanden Bossche H, Marichal P, Odds FC, Le Jeune L, Coene MC: Characterization of an azole-resistant Candida glabrata isolate. Antimicrob Agents Chemother 36:2602-2610, 1992
12. Fidel PL Jr, Vazquez JA, Sobel JD: Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol Rev 12:80-96, 1999
13. Vermitsky JP, Edlind TD: Azole resistance in Candida glabrata: coordinate upregulation of multidrug transporters and evidence for a Pdr1-like transcription factor. Antimicrob Agents Chemother 48:3773-3781, 2004
14. Sobel JD, Chaim W: Treatment of Torulopsis glabrata vaginitis: retrospective review of boric acid therapy. Clin Infect Dis 24:649-652, 1997
15. Shinohara YT, Tasker SA: Successful use of boric acid to control azole-refractory Candida vaginitis in a woman with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 16:219-220, 1997
16. Swate TE, Weed JC: Boric acid treatment of vulvovaginal candidiasis. Obstet Gynecol 43:893-895, 1974
17. Van Slyke KK, Michel VP, Rein MF: Treatment of vulvovaginal candidiasis with boric acid powder. Am J Obstet Gynecol 141:145-148, 1981
18. Jovanovic R, Congema E, Nguyen HT: Antifungal agents vs. boric acid for treating chronic mycotic vulvovaginitis. J Reprod Med 36:593-597, 1991
19. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20:1183-1197, 1997
20. Eckert LO, Hawes SE, Stevens CE, Koutsky LA, Eschenbach DA, Holmes KK: Vulvovaginal candidiasis: clinical manifestations, risk factors, management algorithm. Obstet Gynecol 92:757-765, 1998
21. Fotedar R, Banerjee U: Changing pattern of Candida species in a bone marrow transplant patient. J Infect 32:243-245, 1996
22. Guidelines on Standard Operating Procedures for Laboratory Diagnosis of HIV-Opportunistic Infection. Kumari S, Ed. New Delhi, World Health Org. Regional Office for South East Asia
23. Hosmer DW Jr, Lemeshow S: Applied Logistic Regression. New York, John Wiley & Sons, 1989
24. Geiger AM, Foxman B, Sobel JD: Chronic vulvovaginal candidiasis: characteristics of women with Candida albicans, C glabrata and no candida. Genitourin Med 71:304-307, 1995
25. Horowitz BJ, Edelstein SW, Lippman L: Candida tropicalis vulvovaginitis. Obstet Gynecol 66:229-232, 1985
26. Odds FC: Resistance of yeasts to azole-derivative antifungals. J Antimicrob Chemother 31:463-471, 1993
27. Dennerstein GJ: Depo-Provera in the treatment of recurrent vulvovaginal candidiasis. J Reprod Med 31:801-803, 1986
28. Sanglard D, Ischer F, Calabrese D, Majcherczyk PA, Bille J: The ATP binding cassette transporter gene CgCDR1 from-Candida glabrata is involved in the resistance of clinical isolates to azole antifungal agents. Antimicrob Agents Chemother 43:2753-2765, 1999
29. Gonzalez Ortiz M, Martinez Abundis E: Itraconazole in the treatment of Candida vulvovaginitis in patients with type II diabetes mellitus (non-insulin dependent) Ginecol Obstet Mex 63:15-18, 1995
30. Balbi C, D'Ajello M, Balbi GC: Treatment with ketoconazole in diabetic patients with vaginal candidiasis. Drugs Exp Clin Res 12:413-414, 1986
31. Otero L, Fleites A, Mendez FJ, Palacio V, Vazquez F: Susceptibility of Candida species isolated from female prostitutes with vulvovaginitis to antifungal agents and boric acid. Eur J Clin Microbiol Infect Dis 18:59-61, 1999
32. Carey H: Double blind clinical trial of Borax and Candida in the treatment of vaginal discharge. Comm Br Homoeopath Res Grp 15:12-14, 1986
33. Ruhnke M: Epidemiology of Candida albicans infections and role of non-Candida-albicans yeasts. Curr Drug Targets 7:495-504, 2006
34. Feng Z, Jiang B, Chandra J, Ghannoum M, Nelson S, Weinberg A: Human beta-defensins: differential activity against candidal species and regulation by Candida albicans. J Dent Res 84:445-450, 2005
35. Froy O, Hananel A, Chapnik N, Madar Z: Differential effect of insulin treatment on decreased levels of beta-defensins and Toll-like receptors in diabetic rats. Mol Immunol 44:796-802, 2007